{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:28:11Z","timestamp":1788985691779,"version":"build-2803163510"},"reference-count":43,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000},"content-version":"unspecified","delay-in-days":30,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,12,5]]},"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To investigate clinical characteristics, symptom profile, testing practices, treatment patterns and quality of life (QoL) among patients with pulmonary arterial hypertension (PAH) in Latin America.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Data from the Adelphi Real World PAH Disease Specific Programme, a cross-sectional survey with retrospective data collection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>University\/teaching hospital, regional centres, private practices and government institutions in Argentina, Brazil, Colombia and Mexico.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>246 physicians provided data for 958 patients, of which 533 patients also self-reported data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Mean (SD) patient age was 53.7 (17) years, 70% of patients were female and 79% were WHO functional class (WHO FC) I\u2013II. Overall, 76% had undergone a right heart catheterisation, ranging from 92% in Argentina to 64% in Brazil (p&lt;0.0001). Only 28% underwent a simplified risk assessment strategy in the past 12 months, ranging from 46% in Argentina to 16% in Brazil. Fatigue and dyspnoea on exertion were reported most commonly by physicians (37% and 53%) and patients (68% and 67%). Patient\u2013physician agreement on symptom reporting was minimal-to-weak (kappa, 0.21\u20130.42). PAH-specific combination therapy varied across countries (21% Mexico, 30% Brazil, 70% Colombia and 79% Argentina, p&lt;0.0001)). Overall, 73% of patients received a phosphodiesterase type 5 inhibitor; 52% an endothelin receptor antagonist, 15%\u2009a prostacyclin pathway agent and 11%\u2009a soluble guanylate cyclase stimulator. The mean (SD) EQ-5D (generic instrument to define quality of life)utility ranged from 0.66 (0.20) to 0.70 (0.20) across countries and the mean (SD) EQ-5D Visual Analogue Scale (VAS) was 67.0 (18.10). Lower VAS and utility scores were reported among patients with higher WHO FC (p&lt;0.05).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients reported a high burden of PAH in terms of symptoms and QoL, particularly within higher WHO FC. Low usage of risk assessment strategies and PAH-specific combination therapy was seen in Brazil and Mexico. Further research could identify barriers to prescribing optimal treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-087263","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T11:30:12Z","timestamp":1735644612000},"page":"e087263","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Pathway to care, treatment and disease burden of pulmonary arterial hypertension: a real-world survey of physicians and patients in Latin America"],"prefix":"10.1136","volume":"14","author":[{"given":"Mauricio","family":"Orozco-Levi","sequence":"first","affiliation":[{"name":"Respiratory Department, Hospital Internacional de Colombia-Fundaci\u00f3n Cardiovascular de Colombia, Santander, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rogerio","family":"Souza","sequence":"additional","affiliation":[{"name":"Divis\u00e3o de Pneumologia, Instituto do Cora\u00e7ao, Hospital das Cl\u00ednicas da Faculdade de Medicina da USP, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio M","family":"Bluro","sequence":"additional","affiliation":[{"name":"Hospital Italiano de Buenos Aires, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0497-6719","authenticated-orcid":false,"given":"Julia","family":"Harley","sequence":"additional","affiliation":[{"name":"Adelphi Real World, Bollington, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Luis","family":"Hern\u00e1ndez Oropeza","sequence":"additional","affiliation":[{"name":"Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9015-8666","authenticated-orcid":false,"given":"Adrian","family":"Lescano","sequence":"additional","affiliation":[{"name":"Sanatorio Trinidad Quilmes, Centro Gallego de Buenos Aires, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisela","family":"Meyer","sequence":"additional","affiliation":[{"name":"Departamento de Circula\u00e7\u00e3o Pulmonar, Complexo Hospitalar Santa Casa de Porto Alegre, Porto Alegre, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Pineda","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceuticals, Bogota, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Ramirez","sequence":"additional","affiliation":[{"name":"Unidad de Investigaci\u00f3n Cl\u00ednica en Medicina, Monterrey, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Small","sequence":"additional","affiliation":[{"name":"Adelphi Real World, Bollington, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Valencia","sequence":"additional","affiliation":[{"name":"Clinica Imbanaco, Cali, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1s","family":"Pulido","sequence":"additional","affiliation":[{"name":"Clinical Research Department, Ignacio Ch\u00e1vez National Heart Institute, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,12,31]]},"reference":[{"key":"2025120519295780000_14.12.e087263.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccl.2016.04.001"},{"key":"2025120519295780000_14.12.e087263.2","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.hfc.2018.02.003","article-title":"Pulmonary Arterial Hypertension","volume":"14","author":"Dodson","year":"2018","journal-title":"Heart Fail Clin"},{"key":"2025120519295780000_14.12.e087263.3","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac237"},{"key":"2025120519295780000_14.12.e087263.4","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00879-2022"},{"key":"2025120519295780000_14.12.e087263.5","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv317"},{"key":"2025120519295780000_14.12.e087263.6","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01889-2018","article-title":"Risk stratification and medical therapy of pulmonary arterial hypertension","volume":"53","author":"Gali\u00e8","year":"2019","journal-title":"Eur Respir J"},{"key":"2025120519295780000_14.12.e087263.7","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00116313"},{"key":"2025120519295780000_14.12.e087263.8","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00007-2017","article-title":"Upfront combination therapy reduces right ventricular volumes in pulmonary arterial hypertension","volume":"49","author":"van de Veerdonk","year":"2017","journal-title":"Eur Respir J"},{"key":"2025120519295780000_14.12.e087263.9","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.37765\/ajmc.2021.88610","article-title":"The evolving treatment landscape of pulmonary arterial hypertension","volume":"27","author":"Gale","year":"2021","journal-title":"Am J Manag Care"},{"key":"2025120519295780000_14.12.e087263.10","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1080\/13696998.2017.1363049","article-title":"Healthcare resource utilization and costs for patients with pulmonary arterial hypertension: real-world documentation of functional class","volume":"20","author":"Dufour","year":"2017","journal-title":"J Med Econ"},{"key":"2025120519295780000_14.12.e087263.11","doi-asserted-by":"crossref","DOI":"10.1177\/2045894019880086","article-title":"Medication adherence, hospitalization, and healthcare resource utilization and costs in patients with pulmonary arterial hypertension treated with endothelin receptor antagonists or phosphodiesterase type-5 inhibitors","volume":"10","author":"Frantz","year":"2020","journal-title":"Pulm Circ"},{"key":"2025120519295780000_14.12.e087263.12","doi-asserted-by":"crossref","DOI":"10.1177\/2045894018816294","article-title":"Treatment patterns, healthcare resource utilization, and healthcare costs among patients with pulmonary arterial hypertension in a real-world US database","volume":"9","author":"Studer","year":"2019","journal-title":"Pulm Circ"},{"key":"2025120519295780000_14.12.e087263.13","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-018-0667-8","article-title":"Pulmonary arterial hypertension in Latin America: epidemiological data from local studies","volume":"18","author":"Valverde","year":"2018","journal-title":"BMC Pulm Med"},{"key":"2025120519295780000_14.12.e087263.14","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.2217\/cer-2021-0128","article-title":"Healthcare resource utilization and costs in pediatric pulmonary arterial hypertension in a third-level hospital in Mexico","volume":"10","author":"Garc\u00eda-Aguilar","year":"2021","journal-title":"J Comp Eff Res"},{"key":"2025120519295780000_14.12.e087263.15","doi-asserted-by":"crossref","DOI":"10.1177\/2045894020977300","article-title":"Epidemiology of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: identification of the most accurate estimates from a systematic literature review","volume":"11","author":"Leber","year":"2021","journal-title":"Pulm Circ"},{"key":"2025120519295780000_14.12.e087263.16","doi-asserted-by":"crossref","DOI":"10.1177\/2045894019847643","article-title":"Prevalence of pulmonary arterial hypertension in the Colombian Caribbean","volume":"9","author":"Miranda-Machado","year":"2019","journal-title":"Pulm Circ"},{"key":"2025120519295780000_14.12.e087263.17","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.12012","article-title":"Differences in health policies for drug availability in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension across Latin America","volume":"12","author":"Orozco-Levi","year":"2022","journal-title":"Pulm Circ"},{"key":"2025120519295780000_14.12.e087263.18","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802457040"},{"key":"2025120519295780000_14.12.e087263.19","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1080\/03007995.2023.2279679","article-title":"Real-world evidence generation from patients, their caregivers and physicians supporting clinical, regulatory and guideline decisions: an update on Disease Specific Programmes","volume":"39","author":"Anderson","year":"2023","journal-title":"Curr Med Res Opin"},{"key":"2025120519295780000_14.12.e087263.20","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010352","article-title":"Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the Disease Specific Programme","volume":"6","author":"Babineaux","year":"2016","journal-title":"BMJ Open"},{"key":"2025120519295780000_14.12.e087263.21","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2147\/DMSO.S120101","article-title":"Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015","volume":"9","author":"Higgins","year":"2016","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2025120519295780000_14.12.e087263.22","unstructured":"EuroQol Group . EQ-5D. 2001. Available: https:\/\/euroqol.org"},{"key":"2025120519295780000_14.12.e087263.23","doi-asserted-by":"crossref","first-page":"276","DOI":"10.11613\/BM.2012.031","article-title":"Interrater reliability: the kappa statistic","volume":"22","author":"McHugh","year":"2012","journal-title":"Biochem Med (Zagreb)"},{"key":"2025120519295780000_14.12.e087263.24","unstructured":"European Pharmaceutical Market Research Association . EphMRA. 2021. Available: https:\/\/euroqol.org"},{"key":"2025120519295780000_14.12.e087263.25","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02024-2021","article-title":"Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry","volume":"59","author":"Hoeper","year":"2022","journal-title":"Eur Respir J"},{"key":"2025120519295780000_14.12.e087263.26","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00008211"},{"key":"2025120519295780000_14.12.e087263.27","doi-asserted-by":"publisher","DOI":"10.1378\/chest.14-1036"},{"key":"2025120519295780000_14.12.e087263.28","first-page":"180","article-title":"Collaborative registry of pulmonary hypertension in Argentina (RECOPILAR). Final analysis","volume":"81","author":"Echazarreta","year":"2021","journal-title":"Medicina (B Aires)"},{"key":"2025120519295780000_14.12.e087263.29","doi-asserted-by":"publisher","DOI":"10.1378\/chest.9942"},{"key":"2025120519295780000_14.12.e087263.30","first-page":"144","article-title":"Hipertensi\u00f3n arterial pulmonar: Registro de un centro de referencia en Argentina","volume":"14","author":"Talavera","year":"2014","journal-title":"Rev Am Med Respir"},{"key":"2025120519295780000_14.12.e087263.31","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.37765\/ajmc.2021.88609","article-title":"Pulmonary arterial hypertension: updates in epidemiology and evaluation of patients","volume":"27","author":"Levine","year":"2021","journal-title":"Am J Manag Care"},{"key":"2025120519295780000_14.12.e087263.32","unstructured":"Lescano A , Talavera L , Mazzei J . The advanced functional class and the variables of poor prognosis in pulmonary hypertension. Eur J Heart Fail 2016."},{"key":"2025120519295780000_14.12.e087263.33","article-title":"Epidemiological profile of pulmonary arterial hypertension in Argentina: insights from HINPULSAR registry","volume":"SUPPL 1","author":"Perna","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"2025120519295780000_14.12.e087263.34","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-2417"},{"key":"2025120519295780000_14.12.e087263.35","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.hfc.2018.03.011","article-title":"Right Heart Catheterization for the Diagnosis of Pulmonary Hypertension: Controversies and Practical Issues","volume":"14","author":"D\u2019Alto","year":"2018","journal-title":"Heart Fail Clin"},{"key":"2025120519295780000_14.12.e087263.36","doi-asserted-by":"crossref","DOI":"10.1177\/2045894020948783","article-title":"Right heart catheterization for pulmonary hypertension during the coronavirus disease 2019 pandemic","volume":"10","author":"Qaiser","year":"2020","journal-title":"Pulm Circ"},{"key":"2025120519295780000_14.12.e087263.37","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.vhri.2020.12.002","article-title":"EQ-5D-5L Population Norms and Health Inequality in Colombia","volume":"26","author":"Bailey","year":"2021","journal-title":"Val Health Reg Issues"},{"key":"2025120519295780000_14.12.e087263.38","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-020-02650-y"},{"key":"2025120519295780000_14.12.e087263.39","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2021.675523","article-title":"Health-Related Quality of Life in Patients With Different Diseases Measured With the EQ-5D-5L: A Systematic Review","volume":"9","author":"Zhou","year":"2021","journal-title":"Front Public Health"},{"key":"2025120519295780000_14.12.e087263.40","doi-asserted-by":"crossref","DOI":"10.1177\/2045894020950186","article-title":"Current clinical utilization of risk assessment tools in pulmonary arterial hypertension: a descriptive survey of facilitation strategies, patterns, and barriers to use in the United States","volume":"10","author":"Wilson","year":"2020","journal-title":"Pulm Circ"},{"key":"2025120519295780000_14.12.e087263.41","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.12193","article-title":"Risk assessment validation in patients with pulmonary arterial hypertension: Data from a Southern Brazil registry (RESPHIRAR study)","volume":"13","author":"Spilimbergo","year":"2023","journal-title":"Pulm Circ"},{"key":"2025120519295780000_14.12.e087263.42","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s40256-018-0272-5","article-title":"Pulmonary Arterial Hypertension: Combination Therapy in Practice","volume":"18","author":"Burks","year":"2018","journal-title":"Am J Cardiovasc Drugs"},{"key":"2025120519295780000_14.12.e087263.43","doi-asserted-by":"publisher","DOI":"10.7326\/M22-1460"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-087263","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T03:30:08Z","timestamp":1764991808000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-087263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":43,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12,31]]},"published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1136\/bmjopen-2024-087263"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-087263","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12]]}}}